Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 351

1.

Regulatory T Cells Restrain Pathogenic T Helper Cells during Skin Inflammation.

Hartwig T, Zwicky P, Schreiner B, Yawalkar N, Cheng P, Navarini A, Dummer R, Flatz L, Conrad C, Schlapbach C, Becher B.

Cell Rep. 2018 Dec 26;25(13):3564-3572.e4. doi: 10.1016/j.celrep.2018.12.012.

2.

Cytokine release syndrome as an important differential diagnosis of severe skin toxicity with organ damage during switch from immunotherapy to targeted therapy in metastatic melanoma.

Dimitriou F, Mangana J, Micaletto S, Braun RP, Dummer R.

Melanoma Res. 2019 Feb;29(1):107-108. doi: 10.1097/CMR.0000000000000544. No abstract available.

PMID:
30557221
3.

Adjuvant melanoma therapy with new drugs: should physicians continue to focus on metastatic disease or use it earlier in primary melanoma?

Grob JJ, Garbe C, Ascierto P, Larkin J, Dummer R, Schadendorf D.

Lancet Oncol. 2018 Dec;19(12):e720-e725. doi: 10.1016/S1470-2045(18)30596-5. Review.

PMID:
30507438
4.

Correction: In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2-CDK4/6 Targeting and mTOR-S6 Resistance Mechanisms.

Teh JLF, Cheng PF, Purwin TJ, Nikbakht N, Patel P, Chervoneva I, Ertel A, Fortina PM, Kleiber I, HooKim K, Davies MA, Kwong LN, Levesque MP, Dummer R, Aplin AE.

Cancer Discov. 2018 Dec;8(12):1654. doi: 10.1158/2159-8290.CD-18-1291. No abstract available.

PMID:
30510016
5.

The spectrum of cutaneous adverse events during encorafenib and binimetinib treatment in B-rapidly accelerated fibrosarcoma-mutated advanced melanoma.

Graf NP, Koelblinger P, Galliker N, Conrad S, Barysch M, Mangana J, Dummer R, Cheng PF, Goldinger SM.

J Eur Acad Dermatol Venereol. 2018 Nov 23. doi: 10.1111/jdv.15363. [Epub ahead of print]

PMID:
30468696
6.

Potassium Iodide for Cutaneous Inflammatory Disorders: A Monocentric, Retrospective Study.

Anzengruber F, Mergenthaler C, Murer C, Dummer R.

Dermatology. 2018 Nov 21:1-7. doi: 10.1159/000494614. [Epub ahead of print]

PMID:
30463069
7.

Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors.

Moreira A, Loquai C, Pföhler C, Kähler KC, Knauss S, Heppt MV, Gutzmer R, Dimitriou F, Meier F, Mitzel-Rink H, Schuler G, Terheyden P, Thoms KM, Türk M, Dummer R, Zimmer L, Schröder R, Heinzerling L.

Eur J Cancer. 2019 Jan;106:12-23. doi: 10.1016/j.ejca.2018.09.033. Epub 2018 Nov 17.

PMID:
30453170
8.

Peripheral Blood TCR Repertoire Profiling May Facilitate Patient Stratification for Immunotherapy against Melanoma.

Hogan SA, Courtier A, Cheng PF, Jaberg-Bentele NF, Goldinger SM, Manuel M, Perez S, Plantier N, Mouret JF, Nguyen-Kim TDL, Raaijmakers MIG, Kvistborg P, Pasqual N, Haanen JBAG, Dummer R, Levesque MP.

Cancer Immunol Res. 2019 Jan;7(1):77-85. doi: 10.1158/2326-6066.CIR-18-0136. Epub 2018 Nov 13.

PMID:
30425105
9.

Androgen receptor functions as transcriptional repressor of cancer-associated fibroblast activation.

Clocchiatti A, Ghosh S, Procopio MG, Mazzeo L, Bordignon P, Ostano P, Goruppi S, Bottoni G, Katarkar A, Levesque M, Kölblinger P, Dummer R, Neel V, Özdemir BC, Dotto GP.

J Clin Invest. 2018 Dec 3;128(12):5531-5548. doi: 10.1172/JCI99159. Epub 2018 Nov 5.

10.

Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries.

Kandolf Sekulovic L, Guo J, Agarwala S, Hauschild A, McArthur G, Cinat G, Wainstein A, Caglevic C, Lorigan P, Gogas H, Alvarez M, Duncombe R, Lebbe C, Peris K, Rutkowski P, Stratigos A, Forsea AM, De La Cruz Merino L, Kukushkina M, Dummer R, Hoeller C, Gorry C, Bastholt L, Herceg D, Neyns B, Vieira R, Arenberger P, Bylaite-Bucinskiene M, Babovic N, Banjin M, Putnik K, Todorovic V, Kirov K, Ocvirk J, Zhukavets A, Ymeri A, Stojkovski I, Garbe C.

Eur J Cancer. 2018 Nov;104:201-209. doi: 10.1016/j.ejca.2018.09.013. Epub 2018 Oct 31.

PMID:
30388700
11.

Clinical experience with combination BRAF/MEK inhibitors for melanoma with brain metastases: a real-life multicenter study.

Drago JZ, Lawrence D, Livingstone E, Zimmer L, Chen T, Giobbie-Hurder A, Amann VC, Mangana J, Siano M, Zippelius A, Dummer R, Goldinger SM, Sullivan RJ.

Melanoma Res. 2019 Feb;29(1):65-69. doi: 10.1097/CMR.0000000000000527.

PMID:
30376465
12.

SwissMTB: establishing comprehensive molecular cancer diagnostics in Swiss clinics.

Singer F, Irmisch A, Toussaint NC, Grob L, Singer J, Thurnherr T, Beerenwinkel N, Levesque MP, Dummer R, Quagliata L, Rothschild SI, Wicki A, Beisel C, Stekhoven DJ.

BMC Med Inform Decis Mak. 2018 Oct 29;18(1):89. doi: 10.1186/s12911-018-0680-0.

13.

Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.

Hodi FS, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Cowey CL, Lao CD, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Hill A, Hogg D, Marquez-Rodas I, Jiang J, Rizzo J, Larkin J, Wolchok JD.

Lancet Oncol. 2018 Nov;19(11):1480-1492. doi: 10.1016/S1470-2045(18)30700-9. Epub 2018 Oct 22. Erratum in: Lancet Oncol. 2018 Dec;19(12):e668. Lancet Oncol. 2018 Nov;19(11):e581.

PMID:
30361170
14.

Increased tumour cell PD-L1 expression, macrophage and dendritic cell infiltration characterise the tumour microenvironment of ulcerated primary melanomas.

Koelblinger P, Emberger M, Drach M, Cheng PF, Lang R, Levesque MP, Bauer JW, Dummer R.

J Eur Acad Dermatol Venereol. 2018 Oct 25. doi: 10.1111/jdv.15302. [Epub ahead of print]

PMID:
30357969
15.

A new B-Raf inhibitor combo for advanced melanoma.

Barysch MJ, Mangana J, Dummer R.

Oncotarget. 2018 Oct 2;9(77):34457-34458. doi: 10.18632/oncotarget.26171. eCollection 2018 Oct 2. No abstract available.

16.

Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III Melanoma.

Hauschild A, Dummer R, Schadendorf D, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Schachter J, Lesimple T, Plummer R, Dasgupta K, Haas T, Shilkrut M, Gasal E, Kefford R, Kirkwood JM, Long GV.

J Clin Oncol. 2018 Oct 22:JCO1801219. doi: 10.1200/JCO.18.01219. [Epub ahead of print]

17.

The PROCLIPI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients.

Scarisbrick JJ, Quaglino P, Prince HM, Papadavid E, Hodak E, Bagot M, Servitje O, Berti E, Ortiz-Romero P, Stadler R, Patsatsi A, Knobler R, Guenova E, Child F, Whittaker S, Nikolaou V, Tomasini C, Amitay I, Prag Naveh H, Ram-Wolff C, Battistella M, Alberti-Violetti S, Stranzenbach R, Gargallo V, Muniesa C, Koletsa T, Jonak C, Porkert S, Mitteldorf C, Estrach T, Combalia A, Marschalko M, Csomor J, Szepesi A, Cozzio A, Dummer R, Pimpinelli N, Grandi V, Beylot-Barry M, Pham-Ledard A, Wobser M, Geissinger E, Wehkamp U, Weichenthal M, Cowan R, Parry E, Harris J, Wachsmuth R, Turner D, Bates A, Healy E, Trautinger F, Latzka J, Yoo J, Vydianath B, Amel-Kashipaz R, Marinos L, Oikonomidi A, Stratigos A, Vignon-Pennamen MD, Battistella M, Climent F, Gonzalez-Barca E, Georgiou E, Senetta R, Zinzani P, Vakeva L, Ranki A, Busschots AM, Hauben E, Bervoets A, Woei-A-Jin FJSH, Matin R, Collins G, Weatherhead S, Frew J, Bayne M, Dunnill G, McKay P, Arumainathan A, Azurdia R, Benstead K, Twigger R, Rieger K, Brown R, Sanches JA, Miyashiro D, Akilov O, McCann S, Sahi H, Damasco FM, Querfeld C, Folkes A, Bur C, Klemke CD, Enz P, Pujol R, Quint K, Geskin L, Hong E, Evison F, Vermeer M, Cerroni L, Kempf W, Kim Y, Willemze R.

Br J Dermatol. 2018 Sep 29. doi: 10.1111/bjd.17258. [Epub ahead of print]

PMID:
30267549
18.

The World of Melanoma: Epidemiologic, Genetic, and Anatomic Differences of Melanoma Across the Globe.

Dimitriou F, Krattinger R, Ramelyte E, Barysch MJ, Micaletto S, Dummer R, Goldinger SM.

Curr Oncol Rep. 2018 Sep 24;20(11):87. doi: 10.1007/s11912-018-0732-8. Review.

PMID:
30250984
19.

Immunological effects of BRAF+MEK inhibition.

Ascierto PA, Dummer R.

Oncoimmunology. 2018 Jul 23;7(9):e1468955. doi: 10.1080/2162402X.2018.1468955. eCollection 2018. Review.

PMID:
30228935
20.

Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.

Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, Chiarion Sileni V, Dutriaux C, de Groot JWB, Yamazaki N, Loquai C, Moutouh-de Parseval LA, Pickard MD, Sandor V, Robert C, Flaherty KT.

Lancet Oncol. 2018 Oct;19(10):1315-1327. doi: 10.1016/S1470-2045(18)30497-2. Epub 2018 Sep 12. Erratum in: Lancet Oncol. 2018 Oct;19(10):e509.

PMID:
30219628

Supplemental Content

Loading ...
Support Center